Abstract
Prediction of compounds active against a biological target is a critical step in drug discovery. When data for a novel target is scarce, initial screening must provide the necessary training data for supervised learning models. Traditional methods select initial libraries based on chemical diversity or random selection, which often fail to yield sufficient active compounds. We propose Informer-Based-Ranking (IBR), an approach that utilizes chemogenomic data from previous screenings to select a small "informer set" of compounds. By testing these informers on a novel target and combining the results with historical bioactivity data, we can accurately predict the activity of the remaining library. Prospective tests on two kinase targets (PknB and BGLF4) demonstrate that bioactivity fingerprints outperform traditional chemical fingerprints, enabling the discovery of novel chemical classes through "scaffold hopping."
Introduction: The Cold-Start Problem in Drug Discovery
In the early stages of drug discovery, researchers use virtual screening to prioritize compounds for experimental testing. However, effective computational models typically require existing data on the specific target of interest. For a brand-new target, this creates a "cold-start" problem: how do you choose the first compounds to test when you have no prior information?
Standard approaches involve screening a chemically diverse subset or a random selection of plates. These methods often fail to provide the high-quality data needed to train predictive models for the rest of the library. The IBR strategy addresses this by asking: can we strategically select a tiny fraction of the library—just 16 compounds—to jumpstart highly accurate predictions for the entire set?
Methodology: Informer-Based-Ranking (IBR)
The core innovation of IBR is the shift from chemical fingerprints (what a molecule looks like) to bioactivity fingerprints (how a molecule behaves across hundreds of other targets). By leveraging a "bioactivity matrix" of historical screening data, the authors developed three strategies to select informer sets:
- Regression Selection (RS): Uses statistical techniques to identify compounds that best predict a target's cluster membership.
- Coding Selection (CS): A non-parametric approach treating activity patterns as "code words" to partition the target space.
- Adaptive Selection (AS): Iteratively selects compounds that maximize coverage of the known bioactivity space.
Once the informer set is tested, the new data is integrated with the chemogenomic matrix to rank the remaining compounds.
Key Results and Experimental Validation
The researchers validated IBR using the Published Kinase Inhibitor Sets (PKIS1 & PKIS2), which contain activity data for hundreds of compounds against hundreds of human kinases. To test the model's real-world utility, they conducted prospective laboratory experiments on two kinases not present in the original datasets: PknB (from Mycobacterium tuberculosis) and BGLF4 (from Epstein-Barr virus).
Performance Metrics
In retrospective "leave-one-out" tests on PKIS data, IBR methods significantly outperformed chemical-similarity baselines. As shown in the performance summary below, non-baseline methods like Adaptive Selection (AS) achieved substantially higher median ROCAUC scores compared to traditional chemical structure-based approaches.
Scaffold Hopping and Diversity
Because IBR focuses on biological behavior rather than molecular shape, it successfully identifies active compounds from novel chemical classes—a process known as "scaffold hopping." Prospective lab tests confirmed these results: for both PknB and BGLF4, the RS and CS methods were the only ones to successfully recover multiple hits and diverse chemical classes within the top 10% of their rankings.
Conclusion
Informer-Based-Ranking demonstrates that bioactivity data is a more powerful predictor of target activity than chemical structure alone. Testing just 16 compounds (roughly 4% of the library) was sufficient to achieve high predictive accuracy, offering substantial savings in experimental costs. While the current study focused on kinases, future work will explore the scalability of IBR to ultra-large virtual libraries and its applicability to other protein families.
Summary updated